Prelude Therapeutics vs ProQR Therapeutics
PRLD and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLD and PRQR compare
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 11.4% for ProQR Therapeutics).
ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −270% at Prelude Therapeutics.
Prelude Therapeutics scores higher on the StockData Score (8 against 7 for ProQR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLD | PRQR |
|---|---|---|
| Size and price | ||
| Market cap | $272M | – |
| Share price | $3.41 | $1.18 |
| Change, 1 year | 126% | −45.4% |
| Change, 5 years | −75.6% | −83.6% |
| Beta (5Y) | 1.40 | 2.55 |
| Employees | 79 | 59 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.1× | – |
| P/B | 2.0× | – |
| FCF yield | −12.2% | – |
| Fair value | $2.15 | – |
| Margin of safety | −58.4% | – |
| Growth | ||
| Revenue growth (TTM) | 220% (better) | 11.4% |
| Profitability | ||
| Operating margin | −301% | −233% (better) |
| Net margin | −270% | −229% (better) |
| FCF margin | −148% (better) | −273% |
| Return on equity | −57.7% | −57.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.06 (better) |
| Current ratio | 4.07 (better) | 3.49 |
| Altman Z-score | −2.61 | – |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 62.2% | 57.6% |
| Held by insiders | 40.5% | 37.8% |
| Insider net buying, 12 months | $25.0M (better) | $1.3M |
| Short interest, % of float | 8.8% | – |
Go deeper
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.